Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 4/20 | 0.68 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.54 |
| ▸ | BRD4 | O60885 | 5/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | FABP3 | P05413 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13168622 | 0.81 | SCN4A (1.00) | SCN4ASCN9A | |
| SCHEMBL1386035 | 0.81 | SCN4A (1.00) | SCN4ASCN9A | |
| SCHEMBL3623657 | 0.81 | SCN4A (0.78) | SCN4ASCN9A | |
| SCHEMBL27774526 | 0.80 | SCN4A (0.67) | SCN4ASCN9ABRD4 | |
| SCHEMBL3370179 | 0.76 | SCN4A (0.87) | SCN4ASCN9A | |
| SCHEMBL3623654 | 0.73 | SCN4A (0.52) | SCN4ASCN9ABRD4CARM1 | |
| SCHEMBL21981604 | 0.72 | SCN9A (0.61) | SCN4ASCN9ABRD4 | |
| SCHEMBL1384617 | 0.70 | SCN4A (0.79) | SCN4ASCN9A | |
| SCHEMBL3368969 | 0.70 | SCN9A (1.00) | SCN4ASCN9A | |
| SCHEMBL23069102 | 0.69 | SCN9A (0.55) | SCN4ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013131872-A1 | IMAGING NEURAL ACTIVITY | GE HEALTHCARE LIMITED (GB) | 2013-09-12 | — | — | WO | disclosed |
| US-20100247435-A1 | MEASUREMENT OF NEURAL ACTIVITY | ARSTAD ERIK | 2010-09-30 | — | — | US | disclosed |
| EP-2155260-A1 | MEASUREMENT OF NEURAL ACTIVITY | Hammersmith Imanet, Ltd (GB) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008152109-A1 | MEASUREMENT OF NEURAL ACTIVITY | HAMMERSMITH IMANET LIMITED (GB) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247435-A1 | MEASUREMENT OF NEURAL ACTIVITY | GAP43, ACHE, BDNF | SCN4A 399/4885SCN9A 824/4885BRD4 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.